ChromaDex Corp. on January 15, 2020 announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to consumers in both the European Union and in Australia. ChromaDex received its listing number for Tru Niagen® on the Australian Registry of Therapeutic Goods (ARTG) on January 8, 2020. The Company also received authorization to sell its patented nicotinamide riboside chloride as a novel food in the European Union on January 10, 2020. As the regulatory applicants and innovators, ChromaDex benefits from market exclusivity in Australia until December 2021 and market exclusivity in the EU until February 2025. Niagen® is the only commercially available NR which has twice been successfully reviewed under U.S. Food & Drug Association's (FDA) new dietary ingredient (NDI) notification requirement and has also been successfully notified to the FDA as generally recognized as safe (GRAS). ChromaDex also secured regulatory approval on its patent-protected ingredient in Canada.